Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.39 |
| ▸ | FNTB | P49356 | 8/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 8/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 7/20 | 0.34 |
| ▸ | NPY1R | P25929 | 5/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 4/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CTSH | P09668 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL2330373 | 0.91 | SLC7A5 (0.41) | FNTAFNTBPGGT1BSLC7A5NPY4R | |
| Arginine SCHEMBL8315939 | 0.90 | SLC7A5 (0.40) | FNTAFNTBPGGT1BSLC7A5NPY4R | |
| Arginine SCHEMBL8317787 | 0.90 | SLC7A5 (0.40) | FNTAFNTBPGGT1BSLC7A5NPY4R | |
| Arginine SCHEMBL8587378 | 0.86 | APLNR (0.37) | NPY4RNPY1RNPY2RNPY5RAPLNR | |
| Histidine SCHEMBL2331922 | 0.86 | NPY4R (0.37) | FNTAFNTBPGGT1BSLC7A5NPY4R | |
| Histidine SCHEMBL4778276 | 0.86 | NPY4R (0.40) | SLC7A5NPY4RNPY1RITGB3ITGA2B | |
| Arginine SCHEMBL8318272 | 0.86 | ITGB3 (0.43) | SLC7A5NPY4RNPY1RITGB3ITGA2B | |
| Valine SCHEMBL16992661 | 0.86 | NPY4R (0.35) | SLC7A5NPY4RNPY1RITGB3ITGA2B | |
| Arginine SCHEMBL23362144 | 0.85 | FNTA (0.37) | FNTAFNTBPGGT1BAPLNRCTSL | |
| Arginine SCHEMBL8512347 | 0.85 | FNTA (0.37) | FNTAFNTBPGGT1BAPLNRCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795551-B2 | Tetrapeptides and a method of use as an antioxidant | L'OREAL (FR) | 2017-10-24 | — | — | US | disclosed |
| US-9624265-B2 | Short peptides and a method of use as an antioxidant | L'OREAL (FR) | 2017-04-18 | — | — | US | disclosed |
| US-9464111-B2 | Short peptides and a method of use as an antioxidant | L'OREAL (FR) | 2016-10-11 | — | — | US | disclosed |
| US-20160184208-A1 | SHORT PEPTIDES AND A METHOD OF USE AS AN ANTIOXIDANT | L'OREAL (FR) | 2016-06-30 | — | — | US | disclosed |
| US-20150376234-A1 | SHORT PEPTIDES AND A METHOD OF USE AS AN ANTIOXIDANT | L'OREAL (FR) | 2015-12-31 | — | — | US | disclosed |
| US-20150374606-A1 | TETRAPEPTIDES AND A METHOD OF USE AS AN ANTIOXIDANT | L'OREAL (FR) | 2015-12-31 | — | — | US | disclosed |
| WO-2015200656-A1 | SHORT PEPTIDES AND A METHOD OF USE AS AN ANTIOXIDANT | L'OREAL (FR) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376234-A1 | SHORT PEPTIDES AND A METHOD OF USE AS AN ANTIOXIDANT | LPO, CAT, GPX4 | FNTA 4118/4885FNTB 3459/4885PGGT1B 4544/4885 |
| US-20160184208-A1 | SHORT PEPTIDES AND A METHOD OF USE AS AN ANTIOXIDANT | CUTA, KRT18, LPO | FNTA 4769/4885FNTB 4078/4885PGGT1B 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.